Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New glasses could slow Kids' worsening eyesight

NCT ID NCT06034327

Disease control Sponsor: SightGlass Vision, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether special spectacle lenses can slow the progression of myopia (nearsightedness) in children aged 6 to 8. About 150 kids will wear either the test lenses or regular lenses for up to 3 years. Researchers will measure changes in eye focus and eye length to see if the lenses help control myopia.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
special spectacle lenses designed to slow myopia progression
What this could lead to
If successful, these lenses could offer a simple, non-invasive way to slow worsening nearsightedness in young children, reducing the need for stronger prescriptions.
What could go wrong
This is a mid-stage trial with only 150 children, and results are based on 12-month predictions for 3-year effects. The lenses may not work for all children or may have limited long-term benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 150 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2023

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

6 to 8 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Children 6 - 8 years of age (inclusive) at time of informed consent/assent; 2. Spherical equivalent refractive error between -0.75 and -4.50 D inclusive (by manifest refraction) in each eye; 3. Astigmatism if present, less than or equal to -1.25 DC (by manifest refraction) in each eye; 4. Best corrected visual acuity by manifest refraction of +0.10 logMAR (20/25 Snellen equivalent) or better in each eye; 5. The difference in spherical equivalent power between the two eyes (anisometropia based on manifest refraction) must be less than or equal to 1.50 D; 6. Agree to wear the assigned spectacles constantly except for sleeping, swimming, or other activities in which spectacle wear would be dangerous or otherwise not possible (minimum of 10 hours per day); 7. Ability to comply with study procedures, including high and low contrast visual acuity, axial length, and cycloplegic autorefraction measurements taken for both eyes at the baseline visit; 8. Willingness to participate in the trial for 24 months without contact lens wear; 9. The subject's parent(s) or legal guardian(s) must read, understand and sign the Statement of Informed Consent and receive a fully executed copy of the form. Exclusion Criteria: 1. Subject has previously or currently wears contact lenses (greater than 1-month usage); 2. Current or prior use of bifocals, progressive addition spectacle lenses 3. Current or prior use of any myopia control treatment (e.g., atropine, multifocal contact lenses, orthokeratology); 4. Amblyopia in either eye; 5. Strabismus by cover test at far (4 m) or near (40 cm) wearing distance correction; 6. Any ocular or systemic conditions that could influence refractive development or status \[e.g., keratoconus, congenital glaucoma, ocular trauma, diabetes, Marfan syndrome or other connective tissue disorder, Down's syndrome, family history of poor night vision (to prevent against enrolling subjects with congenital stationary night blindness)\]; 7. Known allergy to proparacaine, tetracaine, or tropicamide; 8. Participation in any investigational clinical study within 30 days of the Baseline visit; 9. Subject's sibling or other household member is already enrolled in this trial.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Juvenile myopia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

myopia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Juvenile myopia Myopia Myopia progression

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    14 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Advanced Eyecare PC

    RECRUITING

    Raytown, Missouri, 64133, United States

  • Athens Eye Care

    RECRUITING

    Athens, Ohio, 45701, United States

  • Bellaire Family Eye Care

    RECRUITING

    Bellaire, Texas, 77401, United States

  • Elsa Pao, OD

    RECRUITING

    Oakland, California, 94607, United States

  • Ilinois College of Optometry

    RECRUITING

    Chicago, Illinois, 60616, United States

  • Kannarr Eye Care

    RECRUITING

    Pittsburg, Kansas, 66762, United States

  • Marietta Eye Clinic

    RECRUITING

    Marietta, Georgia, 30060, United States

  • New England College of Optometry

    RECRUITING

    Boston, Massachusetts, 02115, United States

  • Omega Vision Center

    RECRUITING

    Longwood, Florida, 32779, United States

  • Pacific Rims Optometry

    RECRUITING

    San Francisco, California, 94127, United States

  • Paje Optometric

    RECRUITING

    Santa Ana, California, 92704, United States

  • Procare Vision Centers, Inc.

    RECRUITING

    Granville, Ohio, 43023, United States

  • Scripps Poway Eyecare

    RECRUITING

    San Diego, California, 92131, United States

  • Texas State Optical - Dowlen

    RECRUITING

    Beaumont, Texas, 77706, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.